Hemato Oncology Testing Market

Table of Contents

1 Introduction (Page No. - 13)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Limitations
    1.5 Stakeholders

2 Research Methodology (Page No. - 16)
    2.1 Secondary Data
           2.1.1 Key Data From Secondary Sources
    2.2 Primary Data
           2.2.1 Key Data From Primary Sources
    2.3 Market Size Estimation
           2.3.1 Bottom-Up Approach
           2.3.2 Top-Down Approach
    2.4 Market Breakdown and Data Triangulation
    2.5 Assumptions for the Study

3 Executive Summary (Page No. - 23)

4 Premium Insights (Page No. - 27)
    4.1 Hemato-Oncology Testing: Market Overview
    4.2 North America: Market, By Product and Service (2018)
    4.3 Geographical Snapshot of the Hemato Oncology Testing Market

5 Market Overview (Page No. - 30)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Drivers
                    5.2.1.1 Increasing Incidence of Hematologic Cancer
                    5.2.1.2 Increasing Collaborations
                    5.2.1.3 Increasing Conferences on Personalized Medicine
           5.2.2 Opportunities
                    5.2.2.1 Drug Diagnostics Co-Development
                    5.2.2.2 Emerging Markets
           5.2.3 Restraints
                    5.2.3.1 Uncertain Reimbursement Scenario in Different Regions
                    5.2.3.2 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests
           5.2.4 Challenges
                    5.2.4.1 Intellectual Property Rights Protection Issues

6 Hemato Oncology Testing Market, By Product & Service (Page No. - 37)
    6.1 Introduction
    6.2 Services
           6.2.1 Rising Incidence of Hematologic Cancer to Increase the Demand for Hemato-Oncology Services
    6.3 Assay Kits
           6.3.1 Growing Focus on the Development of Advanced Assay Kits to Drive the Growth of This Market Segment

7 Hemato Oncology Testing Market, By Cancer Type (Page No. - 42)
    7.1 Introduction
    7.2 Leukemia
           7.2.1 Acute Myeloid Leukemia
                    7.2.1.1 Aml is the Most Common Acute Leukemia Affecting Adults
           7.2.2 Acute Lymphocytic Leukemia
                    7.2.2.1 North America Accounted for the Largest Share of the All Segment
           7.2.3 Other Leukemias
    7.3 Lymphoma
           7.3.1 Non-Hodgkin Lymphoma
                    7.3.1.1 Non-Hodgkin Lymphoma Holds the Largest Share of the Market for Lymphoma
           7.3.2 Hodgkin Lymphoma
                    7.3.2.1 APAC Market for Hodgkin Lymphoma Will Grow at the Highest Rate
    7.4 Other Cancers

8 Hemato Oncology Testing Market, By Technology (Page No. - 50)
    8.1 Introduction
    8.2 PCR
           8.2.1 PCR Accounted for the Largest Share of the Market in 2018
    8.3 IHC
           8.3.1 IHC Accounted for the Second-Largest Share of the Market
    8.4 NGS
           8.4.1 NGS is Expected to Register the Highest Growth During the Forecast Period
    8.5 Cytogenetics
           8.5.1 North America Accounted for the Largest Share of the Cytogenetics Market
    8.6 Other Technologies

9 Hemato Oncology Testing Market, By End User (Page No. - 56)
    9.1 Introduction
    9.2 Clinical Laboratories
           9.2.1 Presence of Robust Infrastructure is the Major Driving Factor for This Segment
    9.3 Hospitals
           9.3.1 Hospitals Accounted for the Second-Largest Share of the Market, By End User
    9.4 Academic & Research Institutes
           9.4.1 APAC Market for Academic & Research Institutes Will Grow at the Highest Rate
    9.5 Other End Users

10 Hemato Oncology Testing Market, By Region (Page No. - 62)
     10.1 Introduction
     10.2 North America
             10.2.1 US
                        10.2.1.1 The US Dominates the North American Market
             10.2.2 Canada
                        10.2.2.1 Initiatives Undertaken By Healthcare Authorities in the Country to Ensure the Delivery of Better Public Healthcare to Support the Growth of the Market in Canada
     10.3 Europe
             10.3.1 Rising Focus on Biomarker Development in EU Countries to Support Market Growth
     10.4 Asia Pacific
             10.4.1 Asia Pacific Market to Witness the Highest Growth During the Forecast Period
     10.5 Rest of the World

11 Competitive Landscape (Page No. - 84)
     11.1 Overview
     11.2 Market Ranking Analysis, 2017
     11.3 Key Strategies
             11.3.1 Product Launches & Approvals, 2016–2019
             11.3.2 Expansions, 2016–2019
             11.3.3 Partnerships and Collaborations, 2016–2019
             11.3.4 Acquisitions, 2016–2019

12 Company Profiles (Page No. - 88)
(Business Overview, Products Offered, Recent Developments, MnM View)*
     12.1 F. Hoffman-La Roche Ltd.
     12.2 Abbott Laboratories
     12.3 Qiagen N.V.
     12.4 Thermo Fisher Scientific, Inc.
     12.5 Illumina, Inc.
     12.6 Bio-Rad Laboratories, Inc.
     12.7 Molecularmd (Subsidiary of Icon PLC)
     12.8 Archerdx, Inc.
     12.9 Arup Laboratories Inc.
     12.10 Asuragen, Inc.
     12.11 Invivoscribe, Inc.
     12.12 Adaptive Biotechnologies.

*Details on Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 109)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Available Customizations
     13.5 Related Reports
     13.6 Author Details

List of Tables (77 Tables)

Table 1 Hematologic Cancer Incidence, By Type, 2018–2040
Table 2 Geriatric Population, By Region, 2015 vs 2030
Table 3 Health Expenditure Per Capita, By Country, 2009 vs 2016
Table 4 Incidence of Hematologic Cancers, By Country, 2018 vs 2030
Table 5 Reimbursement Scenario for Hemato-Oncology Testing Products Across Regions
Table 6 Market, By Product & Service, 2017–2024 (USD Million)
Table 7 Hemato-Oncology Testing Services Market, By Region, 2017–2024 (USD Million)
Table 8 Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 9 Hemato-Oncology Testing Assay Kits Market, By Region, 2017–2024 (USD Million)
Table 10 Market, By Cancer Type, 2017–2024 (USD Million)
Table 11 Hemato Oncology Testing Market for Leukemia, By Region, 2017–2024 (USD Million)
Table 12 Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 13 Market for Acute Myeloid Leukemia, By Region, 2017–2024 (USD Million)
Table 14 Market for Acute Lymphocytic Leukemia, By Region, 2017–2024 (USD Million)
Table 15 Market for Other Leukemias, By Region, 2017–2024 (USD Million)
Table 16 Market for Lymphoma, By Region, 2017–2024 (USD Million)
Table 17 Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 18 Market for Non-Hodgkin Lymphoma, By Region, 2017–2024 (USD Million)
Table 19 Hemato Oncology Testing Market for Hodgkin Lymphoma, By Region, 2017–2024 (USD Million)
Table 20 Market for Other Cancers, By Region, 2017–2024 (USD Million)
Table 21 Market, By Technology, 2017–2024 (USD Million)
Table 22 Market for PCR, By Region, 2017–2024 (USD Million)
Table 23 Market for IHC, By Region, 2017–2024 (USD Million)
Table 24 Market for NGS, By Region, 2017–2024 (USD Million)
Table 25 Market for Cytogenetics, By Region, 2017–2024 (USD Million)
Table 26 Hemato Oncology Testing Market for Other Technologies, By Region, 2017–2024 (USD Million)
Table 27 Market, By End User, 2017–2024 (USD Million)
Table 28 Market for Reference Laboratories, By Region, 2017–2024 (USD Million)
Table 29 Market for Hospitals, By Region, 2017–2024 (USD Million)
Table 30 Market for Academic & Research Institutes, By Region, 2017–2024 (USD Million)
Table 31 Market for Other End Users, By Region, 2017–2024 (USD Million)
Table 32 Market, By Region, 2017–2024 (USD Million)
Table 33 North America: Market, By Country, 2017–2024 (USD Million)
Table 34 North America: Market, By Product & Service, 2017–2024 (USD Million)
Table 35 North America: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 36 North America: Market, By Cancer Type, 2017–2024 (USD Million)
Table 37 North America: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 38 North America: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 39 North America: Market, By Technology, 2017–2024 (USD Million)
Table 40 North America: Hemato Oncology Testing Market, By End User, 2017–2024 (USD Million)
Table 41 US: Leukemia at A Glance
Table 42 US: Market, By Product & Service, 2017–2024 (USD Million)
Table 43 US: Market, By Cancer Type, 2017–2024 (USD Million)
Table 44 US: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 45 US: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 46 US: Market, By Technology, 2017–2024 (USD Million)
Table 47 US: Market, By End User, 2017–2024 (USD Million)
Table 48 Canada: Hemato Oncology Testing Market, By Product & Service, 2017–2024 (USD Million)
Table 49 Canada: Market, By Cancer Type, 2017–2024 (USD Million)
Table 50 Canada: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 51 Canada: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 52 Canada: Market, By Technology, 2017–2024 (USD Million)
Table 53 Canada: Market, By End User, 2017–2024 (USD Million)
Table 54 Incidence of Leukemia, By Country, 2018–2035
Table 55 Europe: Market, By Product & Service, 2017–2024 (USD Million)
Table 56 Europe: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 57 Europe: Market, By Cancer Type, 2017–2024 (USD Million)
Table 58 Europe: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 59 Europe: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 60 Europe: Market, By Technology, 2017–2024 (USD Million)
Table 61 Europe: Market, By End User, 2017–2024 (USD Million)
Table 62 Geriatric Population, By Country, 2015 vs 2030
Table 63 Asia Pacific: Market, By Product & Service, 2017–2024 (USD Million)
Table 64 Asia Pacific: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 65 Asia Pacific: Market, By Cancer Type, 2017–2024 (USD Million)
Table 66 Asia Pacific: Hemato Oncology Testing Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 67 Asia Pacific: Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 68 Asia Pacific: Market, By Technology, 2017–2024 (USD Million)
Table 69 Asia Pacific: Market, By End User, 2017–2024 (USD Million)
Table 70 RoW: Market, By Product & Service, 2017–2024 (USD Million)
Table 71 RoW: Hemato-Oncology Testing Services Market, By Type, 2017–2024 (USD Million)
Table 72 RoW: Market, By Cancer Type, 2017–2024 (USD Million)
Table 73 RoW: Market for Leukemia, By Type, 2017–2024 (USD Million)
Table 74 RoW: Hematon Oncology Testing Market for Lymphoma, By Type, 2017–2024 (USD Million)
Table 75 RoW: Market, By Technology, 2017–2024 (USD Million)
Table 76 RoW: Market, By End User, 2017–2024 (USD Million)
Table 77 Ranking of Companies in the Market, 2018

List of Figures (29 Figures)

Figure 1 Hemato Oncology Testing Market
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Market: Bottom-Up Approach
Figure 5 Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Hemato Oncology Testing Market, By Product and Service, 2019 vs 2024 (USD Million)
Figure 8 Market, By Cancer Type, 2019 vs 2024 (USD Million)
Figure 9 Market, By Technology, 2019 vs 2024 (USD Million)
Figure 10 Market, By End User, 2019 vs 2024 (USD Million)
Figure 11 Market, By Region, 2019 vs 2024 (USD Million)
Figure 12 Increasing Incidence of Hematology Cancer to Drive Market Growth
Figure 13 Services to Dominate the North American Market in 2018
Figure 14 North America Accounted for the Largest Market Share in 2018
Figure 15 Hemato Oncology Testing Market: Drivers, Restraints, Opportunities, & Challenges
Figure 16 Market, By Product & Service (2019 vs 2024)
Figure 17 Market, By Cancer Type (2019 vs 2024)
Figure 18 Market, By Technology (2019 vs 2024)
Figure 19 Market, By End User (2019 vs 2024)
Figure 20 Market, By Region (2019 vs 2024)
Figure 21 North America: Hemato Oncology Testing Market Snapshot
Figure 22 Key Developments in the Market From 2016 to 2018
Figure 23 Roche Diagnostic: Company Snapshot (2018)
Figure 24 Abbott Laboratories: Company Snapshot (2018)
Figure 25 Qiagen N.V.: Company Snapshot (2018)
Figure 26 Thermo Fisher Scientific: Company Snapshot (2018)
Figure 27 Illumina, Inc.: Company Snapshot (2018)
Figure 28 Bio-Rad Laboratories, Inc.: Company Snapshot (2018)
Figure 29 Icon PLC: Company Snapshot (2018)

The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study.

Primary Research

Several stakeholders such as hemato oncology testing product manufacturers, vendors, and distributors; researchers; and research associates and scientists from R&D facilities of pharmaceutical industries were consulted for this report. The demand side of this market is characterized by significant use of hemato oncology testing products due to the increasing prevalence of hematologic cancers. The supply side is characterized by advancements in technology and a shift towards advanced products. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the hemato oncology testing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

• The key players in the industry and markets have been identified through extensive secondary research
• The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
• All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the hemato oncology testing industry.

Report Objectives

• To define, describe, and forecast the hemato oncology testing market by product & service, cancer type, technology, end user, and region
• To forecast the revenue of the market segments with respect to four main regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
• To identify the micro-markets with respect to drivers, industry-specific challenges, opportunities, and restraints affecting the growth of the market
• To analyze market segments and subsegments with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To profile the key players and comprehensively analyze their market ranking and core competencies in terms of market developments and growth strategies
• To track and analyze competitive developments such as partnerships, agreements, collaborations, acquisitions, product launches, and research and development activities in the hemato oncology testing market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

• Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
• Geographic Analysis: Further breakdown of the European, Asia Pacific, and the Rest of the World markets into their respective countries
• Company Information: Detailed analysis and profiling of additional market players (up to 5)
• Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market